SIC
CGEM icon

SJS Investment Consulting’s Cullinan Oncology CGEM Stock Holding History

SJS Investment Consulting’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2K Buy
121
+78
+181% +$1.16K ﹤0.01% 1738
2026
Q1 		$612 Buy
43
+23
+115% +$296 ﹤0.01% 1651
2025
Q4 		$207 Buy
+20
New +$180 ﹤0.01% 1799

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

SJS Investment Consulting's CGEM Position: Q2 2026 in Review

SJS Investment Consulting increased its Cullinan Oncology (CGEM) stake by 181% in Q2 2026, buying an estimated $1.16K and bringing the position to 121 shares worth $2.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1738.

SJS Investment Consulting first reported a position in CGEM in Q4 2025 and has held it in 3 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • SJS Investment Consulting held 121 shares of Cullinan Oncology worth $2.2K as of Q2 2026.
  • SJS Investment Consulting bought 78 Cullinan Oncology shares in Q2 2026, an estimated $1.16K.
  • Cullinan Oncology made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1738 holding.
  • SJS Investment Consulting first reported a position in Cullinan Oncology in Q4 2025 and has held it in 3 quarters since.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.